Clarity Pharmaceuticals Ltd. (AU:CU6) has released an update.
Clarity Pharmaceuticals Ltd, a radiopharmaceutical company focused on cancer treatment, has reported a significant revenue increase of 49% in their recent Preliminary Final Report for the year ending June 30, 2024, though the company’s net loss also grew by 72% to $42.3 million. No dividends were paid or declared during the financial period, and the net tangible assets per share rose to 46.9 cents from 26.5 cents in the previous year.
For further insights into AU:CU6 stock, check out TipRanks’ Stock Analysis page.